Additionally, in a Phase I clinical trial (ChinaDrugTrials.org.cn: CTR20170975), APG-115 demonstrated anti-tumor activity against advanced solid tumors, with significant efficacy in tumors that are TP53 wild-type and have MDM2 amplification [195]. This evidence concerns the gene MDM2 and neoplasm.